Shares of Indivior PLC (NASDAQ:INDV - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $8.56, but opened at $9.20. Indivior shares last traded at $9.32, with a volume of 115,911 shares.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on INDV shares. Piper Sandler reaffirmed an "overweight" rating and issued a $15.00 target price (down previously from $22.00) on shares of Indivior in a research report on Friday, October 11th. Craig Hallum decreased their price objective on Indivior from $20.00 to $16.00 and set a "buy" rating for the company in a report on Friday, October 11th.
Check Out Our Latest Research Report on Indivior
Indivior Stock Performance
The stock's 50-day simple moving average is $10.27 and its 200 day simple moving average is $13.93. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.85 and a quick ratio of 0.68. The stock has a market capitalization of $1.21 billion, a P/E ratio of 889.00 and a beta of 0.68.
Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.40 by $0.04. The company had revenue of $299.00 million during the quarter, compared to analysts' expectations of $285.90 million. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. Research analysts expect that Indivior PLC will post 1.7 EPS for the current fiscal year.
Hedge Funds Weigh In On Indivior
Institutional investors and hedge funds have recently modified their holdings of the business. M&G Plc bought a new position in Indivior during the 1st quarter worth $2,518,000. Janus Henderson Group PLC raised its position in Indivior by 14.2% during the first quarter. Janus Henderson Group PLC now owns 440,121 shares of the company's stock valued at $9,424,000 after purchasing an additional 54,750 shares in the last quarter. Vanguard Group Inc. lifted its stake in Indivior by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 5,899,190 shares of the company's stock worth $90,081,000 after purchasing an additional 52,836 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Indivior in the 1st quarter valued at $1,523,000. Finally, Susquehanna International Group Ltd. bought a new position in shares of Indivior in the 2nd quarter valued at $3,224,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.
Indivior Company Profile
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
